Alzheimer’s disease (AD) is one of the most common causes of dementia. The scale of the problem is enormous. In 2010 the total number of people with dementia was estimated at 35.6 million and this number was expected to rise to 115.4 million in 2050. WHO estimated the worldwide costs of treating and caring for those patients at more than US$ 604 billion per year.
Alzheimer’s disease can be effectively treated, but only if it is diagnosed on time (not later than in its third stage). It can occur in any person, so all people aged above 30 are potential candidates for AD tests.
However, commonly used diagnosis methods, such as CT scan or MRI, are too expensive to be used on a wide scale.
Droplet is a medical instrument that allows to diagnose AD at its early stage by measuring the seismic mass of a single drop of blood. It creates a possibility to run affordable screening tests, and start proper treatment on time. This can significantly reduce social and economic costs of treatment and care for patients with AD.
The method is non-invasive. With Droplet, the diagnosis can be done in addition to other, routine blood tests (without taking an additional sample from a patient). On the contrary to other mentioned methods - CT scan or MRI - using Droplet does not require highly-qualified personnel. Therefore, costs of a test are lower. The device itself is also inexpensive.